G6PD rs121909224: Understanding the Mediterranean Variant
The rs121909224 variant in the G6PD gene is widely recognized as the 'Mediterranean' mutation, which leads to a significant reduction in enzyme activity. This genetic change is strongly associated with an increased risk of acute hemolytic anemia when individuals are exposed to specific triggers like fava beans, certain medications, or infections.
What each genotype means
Typical enzyme activity
This genotype represents the common, functional version of the G6PD gene. Individuals with this profile typically produce normal levels of the G6PD enzyme, which helps protect red blood cells from oxidative stress.
This is the most common genotype globally, found in the vast majority of the human population.
Reduced enzyme activity
This genotype is associated with the 'Mediterranean' variant of G6PD deficiency, which can lead to reduced enzyme stability and activity. Because the G6PD gene is on the X chromosome, females with this heterozygous genotype may have a mosaic of red blood cells with both normal and reduced enzyme function. You should discuss any concerns regarding potential triggers, such as fava beans or specific medications, with your clinician or pharmacist.
This genotype is most frequently observed in individuals of Mediterranean, Middle Eastern, and South Asian ancestry.
Significant enzyme deficiency
This genotype indicates the presence of the 'Mediterranean' variant on both X chromosomes in females or the single X chromosome in males, leading to significantly reduced G6PD enzyme activity. This condition can cause severe hemolytic anemia when triggered by certain infections, fava beans, or specific medications. It is essential to consult with your healthcare provider or pharmacist to identify and avoid known triggers for hemolysis.
This genotype is less common than the heterozygous state and is primarily found in populations where the Mediterranean variant is endemic.
What is the rs121909224 Variant?
The rs121909224 variant, often referred to in clinical literature as the G6PD Mediterranean mutation, is a specific change in the DNA sequence of the G6PD gene. Located on the X chromosome, this variant involves a substitution where a cytosine is replaced by a thymine at position 563 (c.563C>T). Because the G6PD gene is located on the X chromosome, the inheritance pattern is X-linked. This means that males, who have only one X chromosome, are more likely to manifest the clinical symptoms of G6PD deficiency if they carry this variant. Females, who have two X chromosomes, may be carriers or, if they inherit the variant on both chromosomes or experience skewed X-inactivation, may also exhibit reduced enzyme activity. This variant is classified as a Class II mutation, which typically results in severe enzyme deficiency.
The Role of the G6PD Gene
The G6PD gene provides instructions for making an enzyme called glucose-6-phosphate dehydrogenase. This enzyme is essential for the proper function of red blood cells, as it helps protect them from oxidative damage. By producing NADPH, the enzyme helps maintain levels of glutathione, a molecule that neutralizes harmful reactive oxygen species that can accumulate during cellular stress. When the G6PD enzyme is deficient or dysfunctional, red blood cells become highly susceptible to oxidative stress. Under normal conditions, individuals with this deficiency may remain asymptomatic. However, when exposed to oxidative triggers—such as certain antimalarial drugs, sulfonamides, or the ingestion of fava beans (a condition known as favism)—the red blood cells can be destroyed prematurely. This process, known as hemolysis, leads to hemolytic anemia, characterized by fatigue, jaundice, and dark urine.
Research and Clinical Evidence
The association between the rs121909224 variant and G6PD deficiency is supported by strong clinical evidence. Research consistently identifies this mutation as a primary cause of G6PD deficiency in populations across the Mediterranean, the Middle East, and parts of the Indian subcontinent. Studies have shown that individuals carrying this variant exhibit significantly lower G6PD enzyme activity compared to those with the wild-type gene. While the clinical severity can vary, the Mediterranean variant is frequently linked to acute hemolytic episodes. It is important to note that while this variant is a well-documented cause of deficiency, it is not the only one; over 1,500 variants exist in the G6PD gene, many of which remain classified as variants of uncertain significance. Clinicians often use genotyping to identify patients at risk, particularly before prescribing medications known to trigger hemolysis in G6PD-deficient individuals.
Population Frequency
The rs121909224 variant is highly prevalent in specific geographic regions, particularly among populations surrounding the Mediterranean Sea, including Southern Europe, North Africa, and the Middle East. It is also found in various communities across the Indian subcontinent. Because of its historical prevalence in these regions, it is often used as a marker in population genetics studies to trace ancestral origins. While it is common in these specific groups, its frequency is significantly lower or absent in other global populations. Genetic screening programs in endemic areas often prioritize testing for this specific variant due to its high clinical relevance in identifying individuals who should avoid specific dietary and pharmacological triggers to prevent hemolytic crises.
Managing Your Genetic Information
Understanding your status regarding the rs121909224 variant can be a valuable tool for personal health management. If you are aware that you or a family member carries this variant, it is essential to discuss this information with a healthcare provider or a clinical pharmacist. They can provide guidance on avoiding specific medications, foods, or environmental exposures that might trigger hemolytic anemia. It is important to remember that genetic information is only one piece of the puzzle; clinical symptoms and enzyme activity levels are the primary factors in medical decision-making. Never make changes to your prescribed medications or diet based solely on a genetic report without consulting a professional. A clinician can help interpret your results in the context of your overall health history and provide a personalized plan to manage potential risks effectively.
How common is this variant?
The rs121909224 variant is common in Mediterranean, Middle Eastern, and South Asian populations, where it is a leading cause of G6PD deficiency.
Frequently asked questions
What is G6PD deficiency?
G6PD deficiency is a genetic condition where the body does not produce enough of the G6PD enzyme. This enzyme is necessary for protecting red blood cells from damage caused by oxidative stress.
Can I eat fava beans if I have this variant?
Individuals with G6PD deficiency are often advised to avoid fava beans, as they contain substances that can trigger hemolysis. You should consult your doctor or a registered dietitian for personalized dietary advice.
Is G6PD deficiency the same as anemia?
G6PD deficiency is a genetic predisposition that can lead to a specific type of anemia called hemolytic anemia. However, not everyone with the deficiency will have chronic anemia; many only experience symptoms when exposed to specific triggers.
How do I know if I have the Mediterranean variant?
The presence of this variant can be determined through genetic testing or by measuring G6PD enzyme activity in the blood. Speak with your primary care physician if you are concerned about your risk.
Are there medications I should avoid?
Yes, certain medications, including some antimalarials and antibiotics, can trigger hemolysis in people with G6PD deficiency. Always inform your pharmacist and doctor about your G6PD status before starting any new medication.
Sources & further reading
Educational information only, last refreshed 9/30/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121909224?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in G6PD
Known as the G6PD A+ variant (p.Asn126Asp), this polymorphism is common in African populations. While it does not cause G6PD deficiency on its own, it is a component of the G6PD A- haplotype, which is associated with reduced enzyme stability and clinical deficiency.
Coding variant associated with G6PD deficiency and susceptibility to acute hemolytic anemia upon oxidative stress or exposure to hemolytic drugs.
Causes the A- variant of G6PD deficiency, common in African populations.
Causes G6PD deficiency and favism risk in Mediterranean populations.
This variant is associated with G6PD deficiency, which can lead to hemolytic anemia upon exposure to certain medications or fava beans.
This variant is a known genetic contributor to G6PD deficiency, impacting drug metabolism and sensitivity to oxidative stress.